Drug major Dr Reddy’s Laboratories has acquired a portfolio of 42 abbreviated new drug applications (ANDAs) in the US. The company has entered into a definitive agreement to acquire yet to be marketed portfolio of ANDAs, including more than 30 generic injectable products. These products will require to be technology transferred and could be launched within the next one to two years.